Hansoh Pharmaceutical Group

Stories

Ex-Akero team takes an oral IL-23 pill public through NextCure merger

Licensor of AVR-001 and co-lead investor in the financing

The team that built Akero Therapeutics and sold it to Novo Nordisk for up to $5.2 billion has a second act. On Tuesday, their new startup, Avere Therapeutics, agreed to merge with struggling public biotech NextCure and raised $320 million to fund it.

Updated Jul 14

Hansoh's B7-H3 ADC wins China breakthrough status for esophageal cancer

New Capabilities

Developer of HS-20093, the lead B7-H3 ADC in China

Patients with advanced esophageal squamous cell carcinoma who fail both chemotherapy and immunotherapy have almost no good options. On May 11, China's drug regulator granted breakthrough status to Hansoh Pharmaceutical's HS-20093, a targeted cancer drug built around a protein called B7-H3.

Updated May 11